The University of Mississippi has a contract with the National Institute on Drug Abuse (NIDA) to carry out a variety of research activities dealing with cannabis, including the Potency Monitoring (PM) program, which provides analytical potency data on cannabis preparations confiscated in the United States. This report provides data on 46,211 samples seized and analyzed by gas chromatography-flame ionization detection (GC-FID) during 1993-2008. The data showed an upward trend in the mean Δ(9)-tetrahydrocannabinol (Δ(9)-THC) content of all confiscated cannabis preparations, which increased from 3.4% in 1993 to 8.8% in 2008. Hashish potencies did not increase consistently during this period; however, the mean yearly potency varied from 2.5-9.2% (1993-2003) to 12.0-29.3% (2004-2008). Hash oil potencies also varied considerably during this period (16.8 ± 16.3%). The increase in cannabis preparation potency is mainly due to the increase in the potency of nondomestic versus domestic samples.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1556-4029.2010.01441.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Complex Relationship Between Cannabis Use and Mental Health: Considering the Influence of Cannabis Use Patterns and Individual Factors.
CNS Drugs
January 2025
Cognitive and Clinical Neuroimaging Core, McLean Hospital, McLean Imaging Center, Belmont, MA, USA.
The relationship between cannabis use and mental health is complex, as studies often report seemingly contradictory findings regarding whether cannabis use results in more positive or negative treatment outcomes. With an increasing number of individuals using cannabis for both recreational (i.e.
View Article and Find Full Text PDFStudy on knowledge and perceptions on the uptake of non-medicinal cannabis-substances and preparations by Portuguese consumers: Borderline issues.
Heliyon
December 2024
CBIOS, Universidade Lusófona's Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024, Lisboa, Portugal.
L.-based food supplement products in pharmacies and para pharmacies in Portugal increased by 84 % between 2021 and 2022, arousing consumers' curiosity. However, information about these products is limited, and consumers are not aware of the restrictions in current European regulations.
View Article and Find Full Text PDFEvaluation of the Association Between Prenatal Cannabis Use and Risk of Developmental Delay.
JAACAP Open
December 2024
University of British Columbia, Vancouver, British Columbia, Canada.
Objective: Conflicting results have arisen regarding the association between prenatal cannabis exposure and risk of parent-reported developmental delay in infancy. In certain instances, this literature has become outdated or failed to adjust for confounding variables. The current study aimed to determine if prenatal cannabis exposure was associated with a greater likelihood of risk of parent-reported developmental delay at 12 months of age in a contemporary cohort, while adjusting for common confounding variables.
View Article and Find Full Text PDFA Double-Blind, Placebo-Controlled Study of Adjunctive Topiramate in Adolescents With Co-Occurring Bipolar and Cannabis Use Disorders.
JAACAP Open
December 2024
University of Cincinnati College of Medicine, Cincinnati, Ohio.
Objective: To evaluate the efficacy of adjunctive topiramate (TPM) for the treatment of cannabis use disorder in adolescents with bipolar I disorder.
Method: We conducted a 16-week, double-blind, randomized, placebo-controlled investigation of quetiapine plus TPM (median dose = 208 mg) vs quetiapine plus placebo in adolescents with bipolar I and cannabis use disorder. All subjects participated in a Motivational Interview and Compliance Enhancement Therapy.
Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials.
Child Adolesc Psychiatry Ment Health
December 2024
University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.
Article Synopsis
- The systematic review investigates the effectiveness of cannabinoids for treating psychiatric disorders in individuals aged 0-25, synthesizing data from randomized placebo-controlled trials.
- The analysis included 8 clinical trials with 474 participants, revealing a modest overall positive effect for symptom improvement, particularly in studies focusing on autism spectrum disorder.
- Adult participants exhibited greater effects from cannabinoid treatment compared to younger populations, with both whole plant and pharmaceutical preparations showing similar efficacy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!